Table 2.
Comparison of IgG antibody levels between first and second visits.
| Groups (n) | 1stV |
2ndV |
|||
|---|---|---|---|---|---|
| Days after COVID-19 + Mean ± SD | 1st IgG Median (IQR) AU/mL | Days after COVID-19 + Mean ± SD | 2nd IgG Median (IQR) AU/mL | Percentage differencea Mean ± SD (%) | |
| Seropositive patients (27) | 41,7 ± 10,1 | 1455,0 (728,2–2874,3) | 200,2 ± 14,4 | 451,1 (366,0–904,7) | -58 ± 34 |
| Male (9) | 43,0 ± 8,2 | 2057,7 (1414,7–2568,4) | 203,8 ± 14,5 | 460,7 (402,6–775,1) | -69 ± 16 |
| Female (18) | 41,0 ± 11,1 | 1222,6 (670,7–3326,6) | 201,0 ± 13,9 | 400,4 (298,9–1121,4) | -52 ± 39 |
| < 6 years (6) | 38,5 ± 10,8 | 3309,8 (2234,9–4968,6) | 205,7 ± 15,5 | 958,4 (518,7–1367,8) | -66 ± 20 |
| ≥ 6 years (21) | 42,6 ± 10,0 | 1360,0 (728,3–2076,1) | 200,1 ± 13,6 | 407,8 (345,2–716,1) | -55 ± 37 |
| Asymptomatic-Mild (23) | 41,6 ± 10,8 | 1455,0 (881,7–2786,3) | 200,1 ± 14,1 | 451,1 (366,1–904,7) | -54 ± 36 |
| Moderate (4) | 42,0 ± 5,6 | 1948,4 (664,6–5815,5) | 212,0 ± 7,0 | 433,9 (176,2–991,1) | -77 ± 6 |
| < 7 days of symptoms (16)b | 40,7 ± 10,2 | 1756,4 (943,5–3182,4) | 202,3 ± 13,2 | 483,8 (384,8–1167,2) | -59 ± 23 |
| ≥ 7 days of symptoms (11) | 42,7 ± 10,7 | 1316,5 (343,0–2786,3) | 201,5 ± 15,4 | 369,1 (221,4–645,5) | -56 ± 47 |
The antibody decrease is statistically significant (p < 0,01) in all groups, except in patients with moderate disease, which was not calculated due to the small sample size.
a
Relative percentage difference in IgG levels from 1st to 2nd visit.
b
Five asymptomatic patients included.